期刊文献+

吡格列酮对原发性高血压伴代谢综合征患者的降压疗效观察 被引量:3

下载PDF
导出
摘要 目的:观察吡格列酮对原发性高血压伴代谢综合征患者血压、糖代谢、血浆胰岛素、脂肪代谢、体重指数的影响。方法:100例原发性高血压伴代谢综合征患者分组进行常规降压治疗组(A组),和常规降压加吡格列酮治疗组(B组),比较两组患者治疗前后血压、糖代谢胰岛素水平、脂代谢和体重指数的变化。结果:(1)常规降压加吡格列酮组患者,血压下降值与常规治疗组相比较,差异有统计学意义,P<0.05。(2)常规降压加吡格列酮组患者胰岛素水平、血脂水平、体重指数明显改善,与常规治疗组比较,差异有统计学意义,P<0.05。结论:吡格列酮能较好地用于原发性高血压伴代谢综合征患者,起到协同降压作用。
出处 《农垦医学》 2012年第2期129-131,共3页 Journal of Nongken Medicine
  • 相关文献

参考文献7

二级参考文献55

共引文献99

同被引文献48

  • 1中华医学会糖尿病学分会代谢综合征研究协作组.中华医学会糖尿病学分会关于代谢综合征的建议[J].中国糖尿病杂志,2004,12(3):156-161. 被引量:3063
  • 2陈灏珠,林果为.实用内科学[M].13版.北京:人民卫生出版社,2009:919.
  • 3Marchi-Alves LM, Rigotti AR, Nogueira MS, et al. Metabolic syndrome components in arterial hypertension[J].Rev Esc En- ferm USP,2012,46(6) : 1348- 1353.
  • 4Koprowski P, Kostkiewicz M, Lesniak - Sobelga A. Echocardio graphic assessment of left atrial volume in asymptomatic ambu- latory patients with metabolic syndrome and/or arterial hyperten sion:is it parameter worth into considerate? [J].Przegl Lek, 2012,69(11) : 1199- 1204.
  • 5Morozova TE, Andrushchishina TB, Oshorova SD.Optimisation of arterial hypertension pharmacotherapy in patients with metabolic syndrome; potential of zofenopril[J].Russian Journal of Cardiol- ogy,2011(4) :63- 68.
  • 6Kinoshita S, Ryuzaki M, Sone M, et al. Effectiveness of using long - acting angiotensin II type 1 receptor blocker in Japanese obese patients with metabolic syndrome on morning hyperten- sion monitoring by using telemedicine system (FWIYAMA study) [J].Clin Exp Hypertens,2014,36(7):508- 516.
  • 7Murakami K,Wada J,Ogawa D, et al .The effects of telmisartan treatment on the abdominal fat depot in patients with metabolic syndrome and essential hypertension, Abdominal fat Depot In- tervention Program of Okayama (ADIPO)[J].Diabetes & Vascu- lar Disease Research, 2013,10( 1 ) : 93 - 96.
  • 8Akyurek O,Akbal E, Gunes F, et al .Peroxisome proliferator- activated receptor gamma concentrations in newly diagnosed hypertension patients and the metabolic effects of olmesartan [J].Archives of Medical Research,2014,45(2) :138 - 142.
  • 9Nedogoda SV, Chumachok EV, Ledyaeva AA, et al. Losartan therapy and hyperuricemia correction in patients with metabolic syndrome and arterial hypertension[J].Cardiovascular Therapy and Prevention, 2011,10(6) : 24 - 29.
  • 10Oleynikov V, Gusakovskaya L, Matrosova I, et al .Indicators of central pressure and rigidity during the long - term therapy of calcium antagonists in patients with metabolic syndrome and hy- pertension[J].Atherosclerosis, 2014,235(2) : E265.

引证文献3

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部